Long-term extension studies and observational drug registers have revealed an increased risk of serious infections in patients treated with anti-tumor necrosis factor agents, particularly infliximab, etanercept and adalimumab. The same may be true for the newer biological drugs rituximab, tocilizumab and abatacept, although this has yet to be confirmed by long-term observational studies. We review the risk of tuberculosis, herpes zoster and other opportunistic infections, and the recommendations for screening for tuberculosis and hepatitis B and C infections in patients with rheumatoid arthritis, with the aim of informing patients and encouraging greater awareness among physicians.
Infections and Biological Therapy in Patients with Rheumatic Diseases / F. Atzeni, A. Batticciotto, I.F. Masala, R. Talotta, M. Benucci, P. Sarzi-Puttini. - In: ISRAEL MEDICAL ASSOCIATION JOURNAL. - ISSN 1565-1088. - 18:3-4(2016 Mar), pp. 164-167.
Infections and Biological Therapy in Patients with Rheumatic Diseases
A. Batticciotto;R. Talotta;P. Sarzi-Puttini
2016
Abstract
Long-term extension studies and observational drug registers have revealed an increased risk of serious infections in patients treated with anti-tumor necrosis factor agents, particularly infliximab, etanercept and adalimumab. The same may be true for the newer biological drugs rituximab, tocilizumab and abatacept, although this has yet to be confirmed by long-term observational studies. We review the risk of tuberculosis, herpes zoster and other opportunistic infections, and the recommendations for screening for tuberculosis and hepatitis B and C infections in patients with rheumatoid arthritis, with the aim of informing patients and encouraging greater awareness among physicians.File | Dimensione | Formato | |
---|---|---|---|
infections.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
120.59 kB
Formato
Adobe PDF
|
120.59 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.